To assess the degree of correlation between the blue peptide-derived Ki affinity and the responsiveness of T cells recognizing those variants, we took advantage of a unique collection of human Melan-A/MART-126-35-derived CD8 T cell clones isolated during phase I vaccination trials in cancer patients (13). Here, CD8A is linked to cancer.